Literature DB >> 21594715

PEGylation improves nanoparticle formation and transfection efficiency of messenger RNA.

Senta Uzgün1, Gabriela Nica, Corinna Pfeifer, Michele Bosinco, Kai Michaelis, Jean-François Lutz, Marc Schneider, Joseph Rosenecker, Carsten Rudolph.   

Abstract

PURPOSE: Cationic polymers have been intensively investigated for plasmid-DNA (pDNA), but few studies addressed their use for messenger-RNA (mRNA) delivery. We analyzed two types of polymers, linear polyethylenimine (l-PEI) and poly-N,N-dimethylaminoethylmethacrylate P(DMAEMA), to highlight specific requirements for the design of mRNA delivery reagents. The effect of PEGylation was investigated using P(DMAEMA-co-OEGMA) copolymer.
METHODS: The influence of polymer structure on mRNA binding and particle formation was assessed in a side-by-side comparison with pDNA by methods such as agarose-retardation assay and scanning probe microscopy. Transfection studies were performed on bronchial epithelial cells.
RESULTS: Binding of cationic polymers inversely correlated with type of nucleic acid. Whereas P(DMAEMA) bound strongly to pDNA, only weak mRNA binding was observed, which was vice versa for l-PEI. Both polymers resulted in self-assembled nanoparticles forming pDNA complexes of irregular round shape; mRNA particles were significantly smaller and more distinct. Surprisingly, PEGylation improved mRNA binding and transfection efficiency contrary to observations made with pDNA. Co-transfections with free polymer improved mRNA transfection.
CONCLUSIONS: Gene delivery requires tailor-made design for each type of nucleic acid. PEGylation influenced mRNA-polymer binding efficiency and transfection and may provide a method of further improving mRNA delivery.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21594715     DOI: 10.1007/s11095-011-0464-z

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  33 in total

Review 1.  mRNA-based gene transfer as a tool for gene and cell therapy.

Authors:  Viggo F I Van Tendeloo; Peter Ponsaerts; Zwi N Berneman
Journal:  Curr Opin Mol Ther       Date:  2007-10

2.  Peptide-mediated RNA delivery: a novel approach for enhanced transfection of primary and post-mitotic cells.

Authors:  T Bettinger; R C Carlisle; M L Read; M Ogris; L W Seymour
Journal:  Nucleic Acids Res       Date:  2001-09-15       Impact factor: 16.971

3.  Expression of therapeutic proteins after delivery of chemically modified mRNA in mice.

Authors:  Michael S D Kormann; Günther Hasenpusch; Manish K Aneja; Gabriela Nica; Andreas W Flemmer; Susanne Herber-Jonat; Marceline Huppmann; Lauren E Mays; Marta Illenyi; Andrea Schams; Matthias Griese; Iris Bittmann; Rupert Handgretinger; Dominik Hartl; Joseph Rosenecker; Carsten Rudolph
Journal:  Nat Biotechnol       Date:  2011-01-09       Impact factor: 54.908

4.  Cellular and molecular barriers to gene transfer by a cationic lipid.

Authors:  J Zabner; A J Fasbender; T Moninger; K A Poellinger; M J Welsh
Journal:  J Biol Chem       Date:  1995-08-11       Impact factor: 5.157

5.  Characterization of tailor-made copolymers of oligo(ethylene glycol) methyl ether methacrylate and N,N-dimethylaminoethyl methacrylate as nonviral gene transfer agents: influence of macromolecular structure on gene vector particle properties and transfection efficiency.

Authors:  Senta Uzgün; Ozgür Akdemir; Günther Hasenpusch; Christof Maucksch; Monika M Golas; Bjoern Sander; Holger Stark; Rabea Imker; Jean-François Lutz; Carsten Rudolph
Journal:  Biomacromolecules       Date:  2010-01-11       Impact factor: 6.988

6.  Purification of polyethylenimine polyplexes highlights the role of free polycations in gene transfer.

Authors:  Sabine Boeckle; Katharina von Gersdorff; Silke van der Piepen; Carsten Culmsee; Ernst Wagner; Manfred Ogris
Journal:  J Gene Med       Date:  2004-10       Impact factor: 4.565

7.  Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial.

Authors:  Albert M Maguire; Katherine A High; Alberto Auricchio; J Fraser Wright; Eric A Pierce; Francesco Testa; Federico Mingozzi; Jeannette L Bennicelli; Gui-shuang Ying; Settimio Rossi; Ann Fulton; Kathleen A Marshall; Sandro Banfi; Daniel C Chung; Jessica I W Morgan; Bernd Hauck; Olga Zelenaia; Xiaosong Zhu; Leslie Raffini; Frauke Coppieters; Elfride De Baere; Kenneth S Shindler; Nicholas J Volpe; Enrico M Surace; Carmela Acerra; Arkady Lyubarsky; T Michael Redmond; Edwin Stone; Junwei Sun; Jennifer Wellman McDonnell; Bart P Leroy; Francesca Simonelli; Jean Bennett
Journal:  Lancet       Date:  2009-10-23       Impact factor: 79.321

Review 8.  Gene therapy for cystic fibrosis.

Authors:  Christian Mueller; Terence R Flotte
Journal:  Clin Rev Allergy Immunol       Date:  2008-12       Impact factor: 8.667

9.  Influenza virus hemagglutinin HA-2 N-terminal fusogenic peptides augment gene transfer by transferrin-polylysine-DNA complexes: toward a synthetic virus-like gene-transfer vehicle.

Authors:  E Wagner; C Plank; K Zatloukal; M Cotten; M L Birnstiel
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-01       Impact factor: 11.205

10.  Development of a novel endosomolytic diblock copolymer for siRNA delivery.

Authors:  Anthony J Convertine; Danielle S W Benoit; Craig L Duvall; Allan S Hoffman; Patrick S Stayton
Journal:  J Control Release       Date:  2008-10-17       Impact factor: 9.776

View more
  12 in total

Review 1.  Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems.

Authors:  S Guan; J Rosenecker
Journal:  Gene Ther       Date:  2017-01-17       Impact factor: 5.250

2.  Charge-altering releasable transporters (CARTs) for the delivery and release of mRNA in living animals.

Authors:  Colin J McKinlay; Jessica R Vargas; Timothy R Blake; Jonathan W Hardy; Masamitsu Kanada; Christopher H Contag; Paul A Wender; Robert M Waymouth
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-09       Impact factor: 11.205

3.  Multifunctional triblock copolymers for intracellular messenger RNA delivery.

Authors:  Connie Cheng; Anthony J Convertine; Patrick S Stayton; James D Bryers
Journal:  Biomaterials       Date:  2012-07-09       Impact factor: 12.479

4.  Biomaterials for mRNA delivery.

Authors:  Mohammad Ariful Islam; Emma K G Reesor; Yingjie Xu; Harshal R Zope; Bruce R Zetter; Jinjun Shi
Journal:  Biomater Sci       Date:  2015-08-17       Impact factor: 6.843

5.  mRNA Vaccine with Antigen-Specific Checkpoint Blockade Induces an Enhanced Immune Response against Established Melanoma.

Authors:  Yuhua Wang; Lu Zhang; Zhenghong Xu; Lei Miao; Leaf Huang
Journal:  Mol Ther       Date:  2017-11-21       Impact factor: 11.454

6.  Neutral Lipopolyplexes for In Vivo Delivery of Conventional and Replicative RNA Vaccine.

Authors:  Federico Perche; Rudy Clemençon; Kai Schulze; Thomas Ebensen; Carlos A Guzmán; Chantal Pichon
Journal:  Mol Ther Nucleic Acids       Date:  2019-07-30       Impact factor: 8.886

7.  Hepatocellular-Targeted mRNA Delivery Using Functionalized Selenium Nanoparticles In Vitro.

Authors:  Dhireshan Singh; Moganavelli Singh
Journal:  Pharmaceutics       Date:  2021-02-24       Impact factor: 6.321

Review 8.  Nanomedicines to Deliver mRNA: State of the Art and Future Perspectives.

Authors:  Itziar Gómez-Aguado; Julen Rodríguez-Castejón; Mónica Vicente-Pascual; Alicia Rodríguez-Gascón; María Ángeles Solinís; Ana Del Pozo-Rodríguez
Journal:  Nanomaterials (Basel)       Date:  2020-02-20       Impact factor: 5.076

Review 9.  Therapeutic Prospects of mRNA-Based Gene Therapy for Glioblastoma.

Authors:  Xiangjun Tang; Shenqi Zhang; Rui Fu; Li Zhang; Kuanming Huang; Hao Peng; Longjun Dai; Qianxue Chen
Journal:  Front Oncol       Date:  2019-11-08       Impact factor: 6.244

Review 10.  Nanovaccine Delivery Approaches and Advanced Delivery Systems for the Prevention of Viral Infections: From Development to Clinical Application.

Authors:  Ana Sara Cordeiro; Yogita Patil-Sen; Maitreyi Shivkumar; Ronak Patel; Abdulwahhab Khedr; Mohamed A Elsawy
Journal:  Pharmaceutics       Date:  2021-12-05       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.